Cargando…

β-(1→3)-D-glucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1β/IL-1 receptor antagonist ratio

BACKGROUND: β-1→3-D-glucans represent a pathogen-associated molecular pattern and are able to modify biological responses. Employing a comprehensive methodological approach, the aim of our in vitro study was to elucidate novel molecular and cellular mechanisms of human peripheral blood immune cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Luhm, Juergen, Langenkamp, Ulrich, Hensel, Jenny, Frohn, Christoph, Brand, Joerg M, Hennig, Holger, Rink, Lothar, Koritke, Petra, Wittkopf, Nadine, Williams, David L, Mueller, Antje
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472690/
https://www.ncbi.nlm.nih.gov/pubmed/16553947
http://dx.doi.org/10.1186/1471-2172-7-5
_version_ 1782127851670077440
author Luhm, Juergen
Langenkamp, Ulrich
Hensel, Jenny
Frohn, Christoph
Brand, Joerg M
Hennig, Holger
Rink, Lothar
Koritke, Petra
Wittkopf, Nadine
Williams, David L
Mueller, Antje
author_facet Luhm, Juergen
Langenkamp, Ulrich
Hensel, Jenny
Frohn, Christoph
Brand, Joerg M
Hennig, Holger
Rink, Lothar
Koritke, Petra
Wittkopf, Nadine
Williams, David L
Mueller, Antje
author_sort Luhm, Juergen
collection PubMed
description BACKGROUND: β-1→3-D-glucans represent a pathogen-associated molecular pattern and are able to modify biological responses. Employing a comprehensive methodological approach, the aim of our in vitro study was to elucidate novel molecular and cellular mechanisms of human peripheral blood immune cells mediated by a fungal β-1→3-D-glucan, i.e. glucan phosphate, in the presence of lipopolysaccharide (LPS) or toxic shock syndrome toxin 1 (TSST-1). RESULTS: Despite an activation of nuclear factor (NF)κB, NFinterleukin(IL)-6 and NFAT similar to LPS or TSST-1, we observed no significant production of IL-1β, IL-6, tumor necrosis factor α or interferon γ induced by glucan phosphate. Glucan phosphate-treated leukocytes induced a substantial amount of IL-8 (peak at 18 h: 5000 pg/ml), likely due to binding of NFκB to a consensus site in the IL-8 promoter. An increase in IL-1receptor antagonist(RA) production (peak at 24 h: 12000 pg/ml) by glucan phosphate-treated cells positively correlated with IL-8 levels. Glucan phosphate induced significant binding to a known NFIL-6 site and a new NFAT site within the IL-1RA promoter, which was confirmed by inhibition experiments. When applied in combination with either LPS or TSST-1 at the same time points, we detected that glucan phosphate elevated the LPS- and the TSST-1-induced DNA binding of NFκB, NFIL-6 and NFAT, leading to a synergistic increase of IL-1RA. Further, glucan phosphate modulated the TSST-1-induced inflammatory response via reduction of IL-1β and IL-6. As a consequence, glucan phosphate shifted the TSST-1-induced IL-1β/IL-1RA ratio towards an anti-inflammatory phenotype. Subsequently, glucan phosphate decreased the TSST-1-induced, IL-1-dependent production of IL-2. CONCLUSION: Thus, β-1→3-D-glucans may induce beneficial effects in the presence of pro-inflammatory responses, downstream of receptor binding and signaling by switching a pro- to an anti-inflammatory IL-1RA-mediated reaction. Our results also offer new insights into the complex regulation of the IL-1RA gene, which can be modulated by a β-1→3-D-glucan.
format Text
id pubmed-1472690
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14726902006-06-01 β-(1→3)-D-glucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1β/IL-1 receptor antagonist ratio Luhm, Juergen Langenkamp, Ulrich Hensel, Jenny Frohn, Christoph Brand, Joerg M Hennig, Holger Rink, Lothar Koritke, Petra Wittkopf, Nadine Williams, David L Mueller, Antje BMC Immunol Research Article BACKGROUND: β-1→3-D-glucans represent a pathogen-associated molecular pattern and are able to modify biological responses. Employing a comprehensive methodological approach, the aim of our in vitro study was to elucidate novel molecular and cellular mechanisms of human peripheral blood immune cells mediated by a fungal β-1→3-D-glucan, i.e. glucan phosphate, in the presence of lipopolysaccharide (LPS) or toxic shock syndrome toxin 1 (TSST-1). RESULTS: Despite an activation of nuclear factor (NF)κB, NFinterleukin(IL)-6 and NFAT similar to LPS or TSST-1, we observed no significant production of IL-1β, IL-6, tumor necrosis factor α or interferon γ induced by glucan phosphate. Glucan phosphate-treated leukocytes induced a substantial amount of IL-8 (peak at 18 h: 5000 pg/ml), likely due to binding of NFκB to a consensus site in the IL-8 promoter. An increase in IL-1receptor antagonist(RA) production (peak at 24 h: 12000 pg/ml) by glucan phosphate-treated cells positively correlated with IL-8 levels. Glucan phosphate induced significant binding to a known NFIL-6 site and a new NFAT site within the IL-1RA promoter, which was confirmed by inhibition experiments. When applied in combination with either LPS or TSST-1 at the same time points, we detected that glucan phosphate elevated the LPS- and the TSST-1-induced DNA binding of NFκB, NFIL-6 and NFAT, leading to a synergistic increase of IL-1RA. Further, glucan phosphate modulated the TSST-1-induced inflammatory response via reduction of IL-1β and IL-6. As a consequence, glucan phosphate shifted the TSST-1-induced IL-1β/IL-1RA ratio towards an anti-inflammatory phenotype. Subsequently, glucan phosphate decreased the TSST-1-induced, IL-1-dependent production of IL-2. CONCLUSION: Thus, β-1→3-D-glucans may induce beneficial effects in the presence of pro-inflammatory responses, downstream of receptor binding and signaling by switching a pro- to an anti-inflammatory IL-1RA-mediated reaction. Our results also offer new insights into the complex regulation of the IL-1RA gene, which can be modulated by a β-1→3-D-glucan. BioMed Central 2006-03-22 /pmc/articles/PMC1472690/ /pubmed/16553947 http://dx.doi.org/10.1186/1471-2172-7-5 Text en Copyright © 2006 Luhm et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Luhm, Juergen
Langenkamp, Ulrich
Hensel, Jenny
Frohn, Christoph
Brand, Joerg M
Hennig, Holger
Rink, Lothar
Koritke, Petra
Wittkopf, Nadine
Williams, David L
Mueller, Antje
β-(1→3)-D-glucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1β/IL-1 receptor antagonist ratio
title β-(1→3)-D-glucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1β/IL-1 receptor antagonist ratio
title_full β-(1→3)-D-glucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1β/IL-1 receptor antagonist ratio
title_fullStr β-(1→3)-D-glucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1β/IL-1 receptor antagonist ratio
title_full_unstemmed β-(1→3)-D-glucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1β/IL-1 receptor antagonist ratio
title_short β-(1→3)-D-glucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1β/IL-1 receptor antagonist ratio
title_sort β-(1→3)-d-glucan modulates dna binding of nuclear factors κb, at and il-6 leading to an anti-inflammatory shift of the il-1β/il-1 receptor antagonist ratio
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472690/
https://www.ncbi.nlm.nih.gov/pubmed/16553947
http://dx.doi.org/10.1186/1471-2172-7-5
work_keys_str_mv AT luhmjuergen b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT langenkampulrich b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT henseljenny b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT frohnchristoph b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT brandjoergm b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT hennigholger b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT rinklothar b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT koritkepetra b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT wittkopfnadine b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT williamsdavidl b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio
AT muellerantje b13dglucanmodulatesdnabindingofnuclearfactorskbatandil6leadingtoanantiinflammatoryshiftoftheil1bil1receptorantagonistratio